Field Notes.

September 13, 2026

GM Is Building Battery Cells It Will Never Sell So It Can Judge the Ones It Buys

GM is finishing a battery plant in Warren, Michigan whose thousands of cells are all for development work, part of $900 million in research and prototype facilities. The output of a pilot line is not cells. It is a process definition and the standing to read what a supplier tells you.

September 12, 2026

Teradyne Is Suing Over Three Universal Robots Patents. All Three Expire in March.

Teradyne Robotics is suing JAKA at the Unified Patent Court over three Universal Robots patents. All three were filed on March 2, 2007 and expire on March 2, 2027. What carries Universal Robots past that date is the 100,000 arms already sold and the decade of integrator and software work around them, which is the part no examiner can put a term limit on.

September 11, 2026

Axogen Paid $200 Million to Widen the Pool of Surgeons Who Can Repair a Nerve

Axogen is paying $200 million in cash for BioCircuit Technologies and its sutureless nerve repair device, NerveTape. The device's value is that the repair no longer needs a surgeon trained in microsuture, which changes how many surgeons can do the operation at all. A closing condition says what Axogen declined to buy.

September 10, 2026

Nine Sites, $1.8 Million: How to Read a Hardware Company's Traction

Agility Robotics' S-4 puts numbers behind a word founders use loosely. More than 65,000 Digit operating hours across nine customer sites, and $1.8 million in 2025 net sales. Almost all of the commercial case for the $2.5 billion SPAC sits inside one unnamed customer's multi-year order, which is a shape worth learning to spot on your own numbers.

September 8, 2026

The Army Bought Its First Production Laser. The Factory Was Funded in March.

AeroVironment committed $30 million to three Albuquerque plants in March and named no customer. In September the Army awarded it $464.8 million for the first production run of a high energy laser weapon. The prototypes had been working for a while, so what the Army bought was the ability to keep building them.

September 7, 2026

Cellares' Machine Met Every Release Spec. Bristol Myers Squibb Still Walked Away.

Bristol Myers Squibb ended a $380 million capacity reservation with Cellares, saying the Cell Shuttle could not make commercial Breyanzi. Cellares says the system already made GMP doses that met every release specification. Both can be true, because clinical release and commercial qualification are different tests.